The endometrial sampler hasn’t meaningfully changed in decades. Until now.
One procedure.
More from a single sample.
Watch how three complementary mechanisms work together to support effective tissue collection.
Here’s what the data shows.
Peer-reviewed in the Journal of Clinical Oncology. Independently validated against final hysterectomy pathology by blinded review.1
In a blinded clinical validation study published in the Journal of Clinical Oncology, Utepreva correctly identified pathology in 91% of cases — including 100% of confirmed malignancies.
Of every patient with confirmed cancer or atypical cells, Utepreva flagged 94% of them. It almost never missed a real problem.
Of every patient who was cancer-free, Utepreva returned a clean result 92% of the time. Almost no false alarms.
Every time Utepreva flagged a malignancy, it was right. No false positives for cancer.
Finally, a procedure
your patients won't dread.
Slim profile. Integrated cervical guard to prevent over-insertion. Twenty-second procedure, no dilation, no sedation. When women aren’t afraid of the procedure, they don’t put it off — and you get the sample you need in one collection with options for multiple testing.
Take the evidence with you.
Independent Study
Independent device testing measuring Utepreva's tissue capture against a leading endometrial sampler. Statistically significant results (p=0.017).
Oncology Study
Peer-reviewed clinical validation study. Blinded review. 94% sensitivity, 92% specificity, 100% positive predictive value for malignancy.
Instructions for Use
Full instructions for provider use, including intended use, procedure steps, contraindications, and device specifications.
Try Utepreva in your practice
And improve endometrial cancer diagnoses, one sampler at a time.
A better way to diagnose endometrial cancer is here.
